论文部分内容阅读
目的 观察阿尔马尔治疗原发性震颤的疗效和安全性。方法 采用多中心开放试验 ,对 30例原发性震颤患者给予阿尔马尔 10mg ,每日一次 ,共 4周。对疗效不好者 ,从第 3周开始增加剂量至 15mg每日一次 ,总计 6周。于治疗前及治疗后第 2 ,4,6周进行症状评分。结果 阿尔马尔治疗原发性震颤的总有效率为 73.4%,而且对正常的血压和心率无明显影响 ,不良反应轻微。结论 阿尔马尔是治疗原发性震颤的有效药物 ,服用方便而且安全。
Objective To observe the efficacy and safety of Armal in the treatment of essential tremor. Methods A multicenter open-label trial was conducted in 30 patients with essential tremor with Almar 10 mg once daily for 4 weeks. For those who do not respond well, increase the dosage to 15mg once daily from the third week for a total of six weeks. Symptom scores were assessed before treatment and at 2, 4 and 6 weeks after treatment. Results The total effective rate of Almar treatment of essential tremor was 73.4%, and had no significant effect on normal blood pressure and heart rate, with mild adverse reactions. Conclusion Armal is an effective drug for the treatment of essential tremor and is convenient and safe to take.